Safety and Efficacy of ASN-002 Combined With a Hedgehog Pathway Inhibitor

  • STATUS
    Recruiting
  • End date
    Dec 25, 2022
  • participants needed
    84
  • sponsor
    Ascend Biopharmaceuticals Ltd
Updated on 25 March 2022
platelet count
carcinoma
neutrophil count
punch biopsy
infertility
vismodegib
asn-002
hedgehog pathway inhibitor

Summary

The primary objectives are to:

  1. Evaluate the safety and tolerability of intralesional ASN-002 when administered in combination with oral vismodegib in patients with Basal Cell Carcinomas (BCC)s;
  2. Evaluate the efficacy of intralesional ASN-002 in target tumours when administered in combination with oral vismodegib in patients with BCCs.

The secondary objective is to:

  1. Evaluate the efficacy of intralesional ASN-002 in non-target tumours when administered in combination with oral vismodegib in patients with BCCs.

The exploratory objective is to:

  1. Evaluate immunological biomarkers during the course of treatment.

Description

Methodology

This study will evaluate ASN-002 (in the dose range 0.5 to 1.5x10(11) vp/mL) with the Hh inhibitor vismodegib (Erivedge®). The study will initially evaluate two Arms receiving 1.0 x 10(11) vp/injection, and following a safety review, may implement further arms in an adaptive study design.

Following screening and baseline biopsies for target and non-target tumours, eligible subjects will be enrolled in the study.

Cycle 1: Treatment with vismodegib (daily dose of 150 mg) for 4 weeks and ASN-002 for 3 weeks (i.e., three ASN-002 injections in total):

  • Day 1 to Day 14 - vismodegib alone
  • Day 15 - vismodegib and ASN-002
  • Day 16 to Day 21 - vismodegib alone
  • Day 22 - vismodegib and ASN-002
  • Day 23 to Day 28 - vismodegib alone
  • Day 29 - ASN-002 alone

Clinical response will be assessed at Week 17, following which, the investigator may where clinically indicated, initiate Cycle 2.

Cycle 2: Treatment with vismodegib (daily dose of 150 mg) for 4 weeks, and one further injection with ASN-002:

  • Day 1 to Day 7 - vismodegib alone
  • Day 8 - vismodegib and ASN-002
  • Day 9 to Day 28 - vismodegib alone

Surgical excision for all patients will occur between Week 25 and Week 33 at the investigators discretion, and dependent on when patient completed study treatment (1 or 2 treatment cycles). Up to 10 BCCs to be excised including 3 target tumours. Excisions can be conducted over 2 visits as per Investigator's discretion.

The Investigator may enrol eligible patients parallel into either Arm 1 or Arm 2, based on the number of tumours present. Up to 10 study BCC tumours (up to 3 target and up to 7 non-target) will be selected per patient.

Following review of at least Week 5 data for N=6 patients in Arm 1 and Arm 2, further Arms with varying doses of ASN-002 (in the dose range 0.5x10(11) vp or 1.5x10(11) vp) may be explored at the discretion of the Safety Review Committee (SRC). Vismodegib or ASN-002 may be evaluated as monotherapies to provide control groups to allow comparison of treatment Arms.

Safety and clinical assessments will be performed at Weeks 1, 3, 4, 5, 7, 17, 25 to 33.

Histological response will be evaluated in all study tumours via excision between Week 25 and Week 33 (as per investigator's discretion).

Six patients will be recruited to each Arm of the study, each Arm may be expanded to 12 patients at the discretion of the SRC.

Details
Condition Basal Cell Carcinoma, Basal Cell Nevus Syndrome
Treatment ASN-002
Clinical Study IdentifierNCT04416516
SponsorAscend Biopharmaceuticals Ltd
Last Modified on25 March 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Histologically confirmed previously untreated, BCC (nodular and superficial), 5-20 mm in maximum diameter, per the selection criteria for study BCC tumours. A punch biopsy (refer to study procedure manual for biopsy size selection) from the thickest part of all the target tumours is required for histological confirmation of BCC and to exclude BCC non-eligible subtypes
Note: If a patient has mix of nodular and superficial BCC tumours, at least
one target tumour should be a nodular BCC
Removal of < 25% of the area of each biopsied tumour by initial biopsy performed 1-12 weeks before Day 1. If the initial biopsy was performed >8 weeks prior to screening, the investigator may re-biopsy the tumour, provided not > 25% of the area of the original tumour is removed. Non-study tumours may be resected or treated at the discretion of the Investigator prior to study entry or if they develop during the study
Hedgehog pathway inhibitor treatment naïve
Acceptable general health as determined by the investigator, i.e. no serious or active medical or psychiatric illness or recreational or therapeutic drug or alcohol use that, in the opinion of the Investigator, would interfere with treatment, assessment or compliance with the protocol, ability to provide informed consent, or patient safety
18 years of age or older
Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2
Screening laboratory values as follows
Female patients who are documented infertile, postmenopausal for at least 1 year
surgically sterile or using acceptable and highly effective birth control for
the duration of the study and for at least 3 months after last administration
Neutrophil count > 1500/mm3
of the study treatments
Haemoglobin > 9 g/dL
Platelet count >100,000/mm3
Prothrombin INR < 1.5
Total bilirubin < 1.5 X upper limit of normal (ULN), except in the case of known Gilbert's syndrome
Aspartate transaminase (AST), alanine transaminase (ALT) or alkaline phosphatase (ALP) < 2X ULN
Creatinine < 1.5 X upper limit of normal (ULN)
Male patients with female partners of child bearing potential, agreement to use two adequate contraception methods while being on vismodegib and for 3 months of completion. agreement not to donate semen for 3 months after completion of vismodegib
Written informed consent prior to initiation of study-specified procedures
Able and willing to comply with all study requirements, including surgical removal of tumour/tumour site at completion of study
Baseline tissue sample adequate for determination of histological or other biomarkers

Exclusion Criteria

Known or suspected metastatic disease or other active, invasive malignancy
Female patients of childbearing potential who are lactating or pregnant (negative serum pregnancy test needed prior to dosing)
Clinically active or uncontrolled skin disease or tattoos that would interfere with evaluation of the area surrounding the target tumour (e.g. eczema, unstable psoriasis, xeroderma pigmentosa)
Known history of sensitivity to any of the ingredients in ASN-002 and any Hh pathway inhibitors
Immunocompromised (e.g. known Hepatitis B or C infection, HIV infection) or receiving or expected to receive an immunomodulating agent (including immunosuppressive agents, cytotoxic drugs, biological agents, immunoglobulins, interferon or other immune or cytokine-based therapies. Use of inhaled or oral corticosteroids at doses higher than physiological replacement doses is an exclusion criterion)
Has received or is expected to receive treatment with psoralen plus UVA or UVB therapy within 6 months of the Screening visit
Any prior systemic anti-tumour therapy or local treatment for target tumours prior to first dose
History of immunological disorder, severe allergic reaction, moderate or severe asthma or known history of anaphylaxis or any other serious adverse reactions to any medication
Any experimental or investigational agents within one month of first ASN-002 injection
Any prior exposure to TG1041, TG1042 (ASN-002), any other adenoviral-based experimental agent, or any form of gene therapy within 6 months of first dose of vismodegib in the study
Any prior exposure to vismodegib or any other Hh inhibitor within 6 months of first dose in the study
Current therapy with any medications recognized to cause rhabdomyolysis or a prior history of rhabdomyolysis
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note